Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Lebret T, Schostak M, Verholen F, Le Berre MA, Srinivasan S, Ortiz J, Mohamed AF, Sarapohja T, Fizazi K. Bögemann M, et al. Among authors: verholen f. Eur Urol. 2023 Mar;83(3):212-221. doi: 10.1016/j.eururo.2022.07.018. Epub 2022 Sep 9. Eur Urol. 2023. PMID: 36089529 Free article. Clinical Trial.
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Shore N, et al. Among authors: verholen f. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0. Target Oncol. 2019. PMID: 31571095 Free PMC article. Clinical Trial.
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandström P, Verholen F, Higano CS, Shore N. George DJ, et al. Among authors: verholen f. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):306-313. doi: 10.1038/s41391-021-00488-0. Epub 2022 Feb 21. Prostate Cancer Prostatic Dis. 2022. PMID: 35190653 Free PMC article.
The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer.
Beyer K, MacLennan SJ, Moris L, Lardas M, Mastris K, Hooker G, Greene R, Briers E, Omar MI, Healey J, Tripathee S, Gandaglia G, Venderbos LDF, Smith EJ, Bjorkqvist J, Asiimwe A, Huber J, Roobol MJ, Zong J, Bjartell A, N'Dow J, Briganti A, MacLennan S, Van Hemelrijck M; PIONEER Consortium; EAU; LU; UNISR; Erasmus; UKE; TAU; KCL; EORTC; TTOP; ICHOM; ECPC; ASSOC EISBM; ICL; Hyve; EAPM; PM; WI; UoA; TUD; Fraunhofer; UGOT; Radboud; IHE; Bayer AG; SANOFI; ASTELLAS; SAS; Janssen; IQVIA; eGF-eCancer; AstraZeneca; HelmHoltz. Beyer K, et al. Eur Urol Focus. 2021 Sep;7(5):943-946. doi: 10.1016/j.euf.2021.09.008. Epub 2021 Oct 1. Eur Urol Focus. 2021. PMID: 34602368 Free article.
177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience.
Sartor O, Fougère C, Essler M, Ezziddin S, Kramer G, Ellinger J, Nordquist L, Sylvester J, Paganelli G, Peer A, Bögemann M, Meltzer J, Sandström P, Verholen F, Song DY. Sartor O, et al. Among authors: verholen f. J Nucl Med. 2022 Mar;63(3):410-414. doi: 10.2967/jnumed.121.262240. Epub 2021 Jun 24. J Nucl Med. 2022. PMID: 34168015 Free PMC article.
Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol.
Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Vradi E, Gandaglia G, Omar MI, MacLennan S, Zong J, Farahmand B, Maclennan SJ, Devecseri Z, Asiimwe A, Collette L, Bjartell A, Ndow J, Briganti A, Van Hemelrijck M; PIONEER Consortium. Beyer K, et al. BMJ Open. 2021 Feb 11;11(2):e040531. doi: 10.1136/bmjopen-2020-040531. BMJ Open. 2021. PMID: 33574142 Free PMC article.
Quality of life and social integration after allogeneic hematopoietic SCT.
Bieri S, Roosnek E, Helg C, Verholen F, Robert D, Chapuis B, Passweg J, Miralbell R, Chalandon Y. Bieri S, et al. Among authors: verholen f. Bone Marrow Transplant. 2008 Dec;42(12):819-27. doi: 10.1038/bmt.2008.253. Epub 2008 Aug 18. Bone Marrow Transplant. 2008. PMID: 18711345
Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants.
Masouridi-Levrat S, Simonetta F, Beauverd Y, Tsopra O, Tirefort Y, Stephan C, Levrat E, Ansari M, Verholen F, Roosnek E, Passweg JR, Chalandon Y. Masouridi-Levrat S, et al. Among authors: verholen f. Bone Marrow Transplant. 2016 Jun;51(6):860-2. doi: 10.1038/bmt.2015.356. Epub 2016 Feb 8. Bone Marrow Transplant. 2016. PMID: 26855156 No abstract available.
28 results